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Background: To date, the coronavirus disease 2019 (COVID-19) caused more than 2.6 million deaths all around the world. Risk factors
for mortality remain unclear. The primary aim was to determine the independent risk factors for 28-day mortality.
Materials and Methods: In this retrospective cohort study, critically ill patients (≥ 18 years) who were admitted to the intensive care
unit due to COVID-19 were included. Patient characteristics, laboratory data, radiologic findings, treatments, and complications were
analyzed in the study.
Results: A total of 249 patients (median age 71, 69.1% male) were included in the study. 28-day mortality was 67.9% (n = 169). The
median age of deceased patients was 75 (66–81). Of them, 68.6% were male. Cerebrovascular disease, dementia, chronic kidney disease,
and malignancy were significantly higher in the deceased group. In the multivariate analysis, sepsis/septic shock (OR, 15.16, 95% CI,
3.96–58.11, p < 0.001), acute kidney injury (OR, 4.73, 95% CI, 1.55–14.46, p = 0.006), acute cardiac injury (OR, 9.76, 95% CI, 1.84–51.83,
p = 0.007), and chest CT score higher than 15 (OR, 4.49, 95% CI, 1.51-13.38, p = 0.007) were independent risk factors for 28-day
mortality.
Conclusion: Early detection of the risk factors and the use of chest CT score might improve the outcomes in patients with COVID-19.
Key words: COVID-19, critical care, tomography, mortality, risk factors, SARS-CoV-2

1. Introduction
The first definition of coronavirus disease 2019
(COVID-19) as unexplained pneumonia was reported
on December 8, 2019, in Hubei Province, Wuhan, China
[1]. The disease spread rapidly, and, as of April 11th,
2021, almost 135 million patients had tested positive
for the disease and around 3 million deaths have been
associated with the disease [2]. Several studies have
defined patient characteristics and outcomes, but
risk factors for mortality remain unclear. Although
the outcomes of the studies vary, older age, male sex,
obesity, hypertension, type 2 diabetes mellitus, active
malignancy, coronary artery disease, a low PaO2 / FiO2
ratio on admission, the need for invasive mechanical
ventilation (IMV), high D-dimer and C-reactive protein

(CRP) levels were defined as risk factors for mortality in
different patient cohorts [3–8].
The rapid spread of COVID-19 increased the stress
on limited intensive care sources in Turkey as well as
around the world. However, it became more difficult to
prevent disease progression and reduce mortality due to
the uncertainty of effective therapies. There are limited
data for critically ill patients with COVID-19 from Turkey,
and we designed the present study to evaluate possible
undefined risk factors for mortality in patients with severe
COVID-19 infection.
In the present study, we aimed to assess patients with
laboratory or clinically confirmed COVID-19 admitted to
the intensive care unit (ICU) and to define the independent
risk factors related to 28-day mortality.
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2. Methods
2.1. Study population
In this retrospective, single-center study, we evaluated the
patients treated in our center’s ICUs due to COVID-19
between March and November 2020. The local ethics
committee (2020/09-39/09.11.2020), and the Turkish
Ministry of Health approved the study. Patients with length
of ICU stay shorter than 24 h were excluded. Written
informed consent was waived due to the study design.
2.2. Data collection
Patient characteristics, epidemiologic, laboratory, and
radiologic data were collected from electronic records
and each patient’s paper charts. Demographic data,
comorbidities, laboratory data including blood tests,
and microbiological cultures, patient characteristics
(body mass index, smoking history, exposure history,
use of immunosuppressive drug), symptoms, and signs
for COVID-19, Acute Physiology and Chronic Health
Evaluation II (APACHE II) score, Charlson comorbidity
index (CCI), Sequential Organ Failure Assessment (SOFA)
score calculated on the ICU admission day were recorded.
The day that the first symptom was noticed considered
the onset of the disease. Hospitalization characteristics
including emergency or in-patient admission, the onset of
symptoms to hospital/ICU admission, length of hospital/
ICU stay, time from hospital admission to ICU admission;
all therapies, including antiviral therapies, corticosteroid
therapy, convalescent plasma transfusion, antithrombotic
therapies, immunomodulator therapies, renal replacement
therapy (RRT), respiratory support modalities were
recorded. Patient’s medical records were screened for
possible complications as sepsis/septic shock, acute cardiac
injury, acute kidney injury (AKI), ventilator-associated
pneumonia (VAP), pulmonary thromboembolism, newonset arrhythmia, and cardiopulmonary resuscitation.
AKI was identified according to KDIGO criteria
[9]. Cardiac injury was defined if the high-sensitive
troponin I levels were above the 99th percentile higher
reference limit [10]. Sepsis and septic shock were defined
according to current guidelines [11]. The diagnosis of
VAP depends on a previous study [12]. Chest computed
tomography (CT) scans were classified as (I) negative, (II)
typical appearance, (III) atypical appearance, and (IV)
indeterminate appearance for COVID-19 pneumonia
according to an expert consensus statement [13]. A scoring
system was used to quantitatively estimate the pulmonary
involvement of the CT scans, which demonstrates a typical
and indeterminate appearance for COVID-19 [14]. All
lung lobes were scored visually from 0 to 5 points. The
total CT score was ranged between 0 to 25. Normal view
with no involvement scored as 0 points. Involvement levels
scored as follows: less than 5%, 1 point; 5%–25%, 2 points;
26%–49%, 3 points; 50%–75%, 4 points, and more than
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75%, 5 points. Atypical CT scans were not scored since
radiologic findings were incompatible with COVID-19.
Two experienced radiologists performed the image
analysis.
2.3. Statistical analysis
The primary outcome of the study was to define independent
risk factors for 28-day mortality in critically ill patients
with COVID-19. Secondary outcome was to determine
clinical characteristics, laboratory data, complications, and
the predictive value of chest CT score for 28-day mortality.
The SPSS Statistics software (Statistical Package for the
Social Sciences Version 24.0; IBM Corporation, Armonk,
NY, USA) was used to perform statistical analysis of the
data. Continuous variables were stated as the median and
interquartile range (IQR) and analyzed using the Mann–
Whitney U test. Categorical variables were stated as counts
and percentages and analyzed by chi-square, or Fisher
exact test. To evaluate the intra-rater agreement for chest
CT scoring, intra-class correlation coefficient (ICC) was
used with a 95% confidence interval (CI). The independent
effect of each factor on 28-day mortality was determined
using logistic regression analysis. A rational method was
used to select a subset of clinically significant covariates.
An odds ratio (OR) with a 95% CI was noticed for each
independent factor. Statistical significance was regarded as
a two-tailed p-value lower than 0.05.
3. Results
3.1. Patient characteristics
A total of 249 patients (69.1%, male) were included in the
study, and patients were divided into two groups: recovered
(n = 80) and deceased (n = 169) (Figure).
The mortality rate was 67.9%. The median age was 71
(61–80) years (Table 1). The median APACHE II score,
CCI, and SOFA score were 20 (12–27), 5 (3–7), and 5
(3–7), respectively. Most of the patients had at least one
or more coexisting comorbidities. Hypertension, diabetes
mellitus, and coronary artery disease were the most
common comorbidities. On hospital admission, dyspnea,
dry cough, and fever were the most common symptoms.
In-patient admissions were more often compared with the
others.
Compared with the recovered group, deceased
patients were significantly older and sicker (with higher
APACHE II, SOFA and CCI scores) and had higher rates
of comorbidities (including cerebrovascular disease,
dementia, chronic kidney disease and malignancy).
Symptoms as expectoration and anorexia were observed
more in this group as well. The median length of ICU
stay was three days longer in the deceased group than the
recovered group, but not statistically significant.
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281 ICU patients screened for eligibility from
March to December 2020.
32 patients excluded,
14, ICU stay shorter than 24 h,
10, data loss,
7, no confirmation of the disease,
1, < 18 year.
249 patients.
Deceased
group
(n = 169)

Recovered
group
(n = 80)

Figure. Flowchart of the study.

3.2. Laboratory data and chest CT findings
In this study, higher median values of white blood cell
(12.4 [8.7–16.1] vs. 9.3 [7.6–12.3] x 103/µL, p = 0.001),
neutrophil counts (10.5 [7.2–14.6] vs. 8.3 [6.2–11.0] × 103/
µL, p = 0.001), as well as higher median levels of blood
urea nitrogen (38.0 [27.0–55.4] vs. 24.0 [18.0–31.5] mg/
dL, p < 0.001), and creatine (1.20 [0.82–1.87] vs. 0.93
[0.73–1.10] mg/dL, p < 0.001) were notable in the deceased
group than the recovered group (Table 2). The median
value of laboratory findings such as C-reactive protein
(164 [80-250] vs. 124 [85-197] mg/L, p = 0.030), ferritin
(640 [377–1134] vs. 482 [255–1061] ng/mL, p = 0.013),
and procalcitonin (0.48 [0.19–1.77] vs. 0.15 [0.08–0.32]
ng/mL, p < 0.001), high-sensitive troponin I (38.0 [15.0–
313.0] vs. 11.5 [6.7–40.0] ng/L, p < 0.001), plasma brain
natriuretic peptide (120 [46–379] vs. 51 [27–172] pg/mL,
p < 0.001), and D-dimer (2.0 [1.2–3.9] vs. 1.0 [0.5–2.0] µg/
mL, p < 0.001) were higher in the deceased group than the
recovered group.
In the deceased group, the median values of pH (7.37
[7.29–7.46] vs. 7.44 [7.39–7.48], p < 0.001), PaO2 / FiO2
ratio (112 [91–144] vs. 129 [108–162], p = 0.001), HCO3
(22.0 [18.2–25.0] vs. 24.0 [21.4–26.0] mmol/L, p < 0.001),
oxygen saturation on ICU admission (91 [86–94] vs. 93
[90–96], p = 0.002) were lower than the recovered group.
Patients had a lower PaO2 / FiO2 ratio than 200 (153
[90.5%] vs. 64 [80.0%], p = 0.026), and 100 (63 [37.3%] vs.
12 [15.0%] p < 0.001), and higher median values of lactate
(2.1 [1.4–3.3] vs. 1.8 [1.3–2.4] mmol/L, respectively, p =
0.001) were more frequent in the deceased group than the
recovered group.

Analysis of the bloodstream infection, VAP, and
urinary tract infection showed that the number of patients
with one or higher positive blood cultures (53 [31.4%] vs.
11 [13.8%], respectively, p = 0.003), and respiratory sample
cultures (83 [49.1%] vs. 13 [16.3%], respectively, p < 0.001);
and tracheal aspirate cultures including Acinetobacter spp.
(39 [23.1%] vs. 8 [10.0%], p = 0.015) and Klebsiella spp. (19
[11.2%] vs. 1 [1.3%], p = 0.005) were significantly high in
the deceased group than the recovered group.
Of all, 230 patients had a chest CT scan performed on
hospital admission. Chest CT scans were reevaluated by
two radiologists to calculate the CT scores. ICC revealed
a high interrater reliability between raters (ICC: 0.995;
95% CI, 0.991–0.998). Chest CT scan compatibility for
COVID-19 pneumonia distributed as typical (77.9%),
atypical (10.8%), indeterminate appearance (2.0%), and
negative (1.6%). The median chest CT score was 15 (10–
20). Although the median chest CT score was higher in the
deceased group than the recovered group (16 [12–20] vs. 13
[9–19], respectively), there was no statistical significance
between the groups (p = 0.05). Additionally, participants
divided into two groups referring to the median chest CT
score and patients who had a chest CT score more than 15
were significantly higher in the deceased group than the
recovered group (79 [46.7%] vs. 27 [33.8%], p = 0.034).
3.3. Treatments and complications
Most patients received antiviral therapies (favipiravir
[96.0%], hydroxychloroquine [21.7%]), corticosteroid
therapy (corticosteroid [78.3%], pulse corticosteroid
[40.6%]) depending on current national treatment
guidelines at the time of hospitalization (Table 3).
Tocilizumab was given to 25 (10.0%) patients. Of all
cases, 70 (28.1%) patients were transfused different
amounts of convalescent plasma. Favipiravir treatment
was significantly high in the recovered group than the
deceased group (100% vs. 94.1%, respectively, p = 0.033).
RRT (34.3% vs. 8.8%, p < 0.001) and vasopressor use
(84.6% vs. 27.5%, p < 0.001) were more common in the
deceased group than the recovered group. Respiratory
support modalities distributed as conventional oxygen
therapy (COT) (8.0%), high flow nasal cannula (HFNC)
(36.1%), noninvasive mechanical ventilation (NIMV)
(17.3%), invasive mechanical ventilation (IMV) (77.1%),
extracorporeal membrane oxygenation (ECMO) (1.2%).
HFNC was more frequently used in the recovered group
than the deceased group (52.5% vs. 28.4%, p < 0.001), and
patients in the deceased group more frequently needed
IMV than the recovered group (97.6% vs. 33.8%, p <
0.001). Patients who did not need any respiratory support
except COT were significantly higher in the recovered
group than the deceased group (22.5% vs. 1.2%, p < 0.001).
The most common complications among 249
patients were sepsis/septic shock (66.7%), AKI (55.8%),
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Table 1. Baseline characteristics of the patients.
28-day status
Clinical Characteristics

All cases
(n=249)

Recovered group
(n=80)

Deceased group
(n=169)

P Value

Age, years

71 (61-80)

63 (53-71)

75 (66-81)

< 0.001

Male

172 (69.1)

24 (30.0)

116 (68.6)

Female

77 (30.9)

56 (70.0)

53 (31.4)

BMI, kg/m2

26.1 (23.8-29.3)

27.0 (24.0-29.9)

26.0 (23.3-29.0)

0.21

APACHE II score

20 (12-27)

14 (9-22)

23 (15-28)

< 0.001

SOFA Score

Sex
0.88

5 (3-7)

4 (2-5)

6 (4-8)

< 0.001

CCI

5 (3-7)

2 (1-5)

6 (4-8)

< 0.001

Smoking history

55 (22,1)

13 (16.3)

42 (24.9)

0.14

Exposure history

87 (34.9)

26 (32.5)

61 (36.1)

0.67

Immunosuppressive drug use

15 (6.0)

5 (6.3)

10 (5.9)

1.00

RT-PCR test positivity

222 (89.2)

66 (82.5)

156 (92.3)

0.028

Comorbidities

215 (86.3)

61 (76.3)

154 (91.1)

0.003

Hypertension

178 (71.5)

52 (65.0)

126 (74.6)

0.13

Diabetes mellitus (Type 2)

96 (38.6)

29 (36.3)

67 (39.6)

0.68

Coronary artery disease

64 (25.7)

15 (18.8)

49 (29.0)

0.09

Congestive heart failure

35 (14.1)

6 (7.5)

29 (17.2)

0.05

Chronic kidney disease

38 (15.3)

6 (7.5)

32 (18.9)

0.023

Dementia

30 (12.0)

3 (3.8)

27 (16.0)

0.006

COPD

29 (11.6)

9 (11.3)

20 (11.8)

1.00

Malignancy b

25 (10.0)

3 (3.8)

22 (13.0)

0.024

Cerebrovascular diseases

17 (6.8)

0 (0.0)

17 (10.1)

0.002

Hyperlipidemia

16 (6.4)

6 (7.5)

10 (5.9)

0.59

Parkinson’s disease

7 (2.8)

1 (1.3)

6 (3.6)

0.44

Thromboembolic event history

5 (2.0)

2 (2.5)

3 (1.8)

0.66

Chronic liver disease

1 (0.4)

0 (0.0)

1 (0.6)

1.00

Dyspnea

172 (69.1)

49 (61.3)

123 (72.8)

0.08

Dry cough

122 (49.0)

41 (51.3)

81 (47.9)

0.68

Fever

118 (47.4)

41 (51.3)

77 (45.6)

0.42

Fatigue

76 (30.5)

32 (40.0)

44 (26.0)

0.028

Myalgia

36 (14.5)

18 (22.5)

18 (10.7)

0.020

Expectoration

32 (12.9)

3 (3.8)

29 (17.2)

0.002

Nausea/Vomiting

29 (11.6)

7 (8.8)

22 (13.0)

0.40

Anorexia

24 (9.6)

3 (3.8)

21 (12.4)

0.037

Chest pain

20 (8.0)

8 (10.0)

12 (7.1)

0.46

Sore throat

16 (6.4)

8 (10.0)

8 (4.7)

0.16

Diarrhea

11 (4.4)

3 (3.8)

8 (4.7)

1.00

Loss of smell or taste

10 (4.0)

4 (5.0)

6 (3.6)

0.73

Headache

8 (3.2)

4 (5.0)

4 (2.4)

0.27

a

Signs and symptoms
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Table 1. (Contuned).
Palpitations

7 (2.8)

2 (2.5)

5 (3.0)

1.00

Abdominal pain

5 (2.0)

0 (0.0)

5 (3.0)

0.18

Hospital admission, days

3 (1-6)

3 (2-6)

3 (1-5)

0.08

ICU admission, days

6 (3-10)

8 (4-10)

6 (3-10)

0.21

In-patient

166 (66.7)

57 (71.3)

109 (64.5)

Emergency

83 (33.3)

23 (28.8)

60 (35.5)

Length of Hospital stay before ICU admission, days

2 (1-5)

2 (1-5)

2 (1-5)

0.58

Length of ICU stay, days

8 (4-14)

6 (4-13)

9 (4-14)

0.25

Length of hospital stay, days

14 (9-21)

17 (12-25)

13 (8-19)

< 0.001

Hospitalization characteristics
Onset of symptom to,

Admission,
0.32

All values are expressed as numbers (percentages) or median (interquartile range).
Abbreviations: BMI, body mass index; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA score, The Sequential
Organ Failure Assessment Score; CCI, Charlson Comorbidity Index; RT-PCR test; real time – polymerase chain reaction test; COPD,
chronic obstructive pulmonary disease; ICU, intensive care unit.
a
Calculated on the day of ICU admission.
b
Includes hematological and solid organ malignancies.

VAP (47.4%), acute cardiac injury (24.1%), new-onset
arrhythmia (20.1%). Of these complications, sepsis/
septic shock (87.6% vs. %22.5, p < 0.001), AKI (74.0% vs.
17.5%, p < 0.001), VAP (60.4% vs. 20.0%, p < 0.001), acute
cardiac injury (32.0% vs. 7.5%, p < 0.001), and new-onset
arrhythmia (23.7% vs. 12.5%, p = 0.043) were particularly
higher in the deceased group than the recovered group.
3.4 Multivariate model for independent risk factors for
mortality
Logistic regression analysis was conducted to define the
independent risk factors for 28-day mortality (Table 4).
The model was built by considering patient characteristics
such as sex, APACHE II score and chest CT score > 15,
comorbidities including malignancy and dementia, and
complications, which are also risk factors for mortality,
such as AKI, VAP, sepsis/septic shock, and acute cardiac
injury. The analysis determined the independent risk
factors for 28-day mortality as follows: sepsis/septic shock
(OR, 15.16, 95% CI, 3.96–58.11, p < 0.001); AKI (OR, 4.73,
95% CI, 1.55–14.46, p = 0.006); CT score higher than 15
on hospital admission (OR, 4.49, 95% CI, 1.51–13.38, p =
0.007); and acute cardiac injury (OR, 9.76, 95% CI, 1.84–
51.83, p = 0.007).
4. Discussion
In the present study, we wanted to assess critically ill patients
with clinically or laboratory-confirmed COVID-19. We
determined the mortality with a rate of 67.9% and found
that a chest CT score > 15 on hospital admission and
complications including sepsis/septic shock, AKI, and

acute cardiac injury independently increase the risk of
death.
The mortality rate is higher than expected however
we believe the study population consisted of many frail
elderly high-risk patients with a high prevalence of organ
dysfunction that occurred due to complications as sepsis/
septic shock, AKI, acute cardiac injury. Moreover, a high
proportion of the patients had PaO2 / FiO2 ratio lower
than 200 on ICU admission (87.1%) with high intubation
rate (77.1%). A case series from the USA revealed high
mortality with a rate of 67% as well as this present study
[15]. In the case series, the median age was 70 (43–92)
years and 85.7% of the patients had at least one or more
comorbidities especially CKD, congestive heart failure,
diabetes mellitus, and COPD. Of them, 57.1% had severe
ARDS, but the median PaO2/FiO2 ratio was higher
compared with this presented study (169 [69–492] vs. 116
[97–152] mmHg). Additionally, complications including
cardiomyopathy (33.3%), acute kidney failure (19.1%),
and acute hepatic injury (14.3%) were notable. Beyond all,
the small number of patients (n=21) in the case series was
the main limitation to generalize the results.
In critically ill patients with COVID-19, 28-day
mortality varies among studies ranging between 35.4%–
67% [5,7,8,10,15,16]. In a case series from China, 28-day
ICU mortality was 39% but reached 97% in the subgroup
of patients requiring IMV [17]. Another study reported
88.1% ICU mortality in patients who received IMV [18].
Conversely, in a case series with a high proportion of
patients who needed IMV (79%), 28-day mortality was
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Table 2. Laboratory data, microbiological culture results, and chest CT findings.
28-day status
Laboratory Data a

All cases
(n=249)

Recovered group
(n=80)

Deceased group
(n=169)

P Value

WBC, x 103/µL

11.2 (8.1-15.0)

9.3 (7.6-12.3)

12.4 (8.7-16.1)

0.001

Neutrophil, x 10 /µL

9.6 (6.8-13.8)

8.3 (6.2-11.0)

10.5 (7.2-14.6)

0.001

Hemoglobin, g/dL

12.5 (11.0-13.8)

12.9 (11.6 -13.9)

12.3 (10.4-13.8)

0.05

Lymphocyte, x 10 /µL

0.5 (0.3-0.9)

0.5 (0.3-0.8)

0.5 (0.3-1.0)

0.61

Lymphocyte, %

5.6 (3.1-8.9)

6.1 (4.1-10.3)

5.2 (2.8-8.4)

0.10

Platelet, x 10 /µL

252.0 (172.0-334.5)

273.5 (184.3-341.8)

243.0 (167.5-332.0)

0.26

BUN, mg/dL

31.0 (23.0-50.0)

24.0 (18.0-31.5)

38.0 (27.0-55.4)

< 0.001

Creatinine, mg/dL

1.00 (0.80-1.60)

0.93 (0.73-1.10)

1.20 (0.82-1.87)

< 0.001

Total Bilirubin, mg/dL

0.8 (0.6-1.14)

0.7 (0.6-1.1)

0.9 (0.7-1.2)

0.22

CRP, mg/L

152 (83-228)

124 (85-197)

164 (80-250)

0.030

AST, U/L

52 (37-89)

51 (34-77)

54 (39-93)

0.13

ALT, U/L

37 (24-63)

40 (26-63)

36 (23-62)

0.14

LDH, U/L

550 (421-706)

495 (389-646)

570 (452-761)

0.006

Ferritin, ng/mL

612 (345-1118)

482 (255-1061)

640 (377-1134)

0.013

HS Troponin I, ng/L

27.0 (9.6-142.5)

11.5 (6.7-40.0)

38.0 (15-313)

< 0.001

D-Dimer, µg/mL

1.5 (0.9-3.6)

1.0 (0.5-2.0)

2.0 (1.2-3.9)

< 0.001

Procalcitonin, ng/mL

0.34 (0.13-1.12)

0.15 (0.08-0.32)

0.48 (0.19-1.77)

< 0.001

BNP (plasma), pg/mL

87 (39-307)

51 (27-172)

120 (46-379)

< 0.001

pH

7.41 (7.32-7.47)

7.44 (7.39-7.48)

7.37 (7.29-7.46)

< 0.001

PaCO2, mmHg

35 (30-42)

33 (30-38)

36 (30-44)

0.08

PaO2, mmHg

65 (54-79)

68 (58-80)

63 (53-78)

0.09

HCO3, mmol/L

22.8 (20-25)

24.0 (21.4-26.0)

22.0 (18.2-25.0)

< 0.001

Lactate, mmol/L

2.0 (1.4-3.0)

1.8 (1.3-2.4)

2.1 (1.4-3.3)

0.001

SO2, %

92 (87-95)

93 (90-96)

91 (86-94)

0.002

FiO2, %

60 (50-60)

50 (50-60)

60 (50-60)

< 0.001

PaO2 / FiO2

116 (97-152)

129 (108-162)

112 (91-144)

0.001

PaO2 / FiO2 ≤ 100

75 (30.1)

12 (15.0)

63 (37.3)

< 0.001

PaO2 / FiO2 ≤ 200

217 (87.1)

64 (80.0)

153 (90.5)

0.026

100< PaO2 / FiO2 ≤ 200

142 (57.0)

52 (65.0)

90 (53.3)

0.10

200< PaO2 / FiO2 ≤ 300

21 (8.4)

11 (13.8)

10 (5.9)

0.05

PaO2 / FiO2 > 300

11 (4.4)

5 (6.3)

6 (3.6)

0.34

Blood culture

3

3

3

Arterial blood gas analysis a
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64 (25.7)

11 (13.8)

53 (31.4)

0.003

Acinetobacter spp.

34 (13.7)

8 (10.0)

26 (15.4)

0.32

Klebsiella spp.

13 (5.2)

2 (2.5)

11 (6.5)

0.23

Enterobacter spp.

13 (5.2)

3 (3.8)

10 (5.9)

0.56

Pseudomonas spp.

5 (2.0)

1 (1.3)

4 (2.4)

1.00

Respiratory sample culture

96 (38.6)

13 (16.3)

83 (49.1)

< 0.001

Acinetobacter spp.

47 (18.9)

8 (10.0)

39 (23.1)

0.015

Klebsiella spp.

20 (8.0)

1 (1.3)

19 (11.2)

0.005

b
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Table 2. (Contuned).
Pseudomonas spp.

7 (2.8)

2 (2.5)

5 (3.0)

1.00

Enterobacter spp.

2 (0.8)

0 (0.0)

2 (1.2)

1.00

Urine Culture

70 (28.1)

19 (23.8)

51 (30.2)

0.37

Acinetobacter spp.

5 (2.0)

2 (2.5)

3 (1.8)

0.66

Klebsiella spp.

10 (4.0)

3 (3.8)

1 (1.3)

1.00

Pseudomonas spp.

3 (1.2)

1 (1.3)

2 (1.2)

1.00

Enterobacter spp.

11 (4.4)

3 (3.8)

8 (4.7)

1.00

Escherichia coli

20 (8.0)

6 (7.5)

14 (8.3)

1.00

Candida spp.

23 (8.2)

7 (8.8)

16 (9.5)

1.00

Chest CT Score c

15 (10-20)

13 (9-19)

16 (12-20)

0.05

Chest CT Score > 15

106 (42.6)

27 (33.8)

79 (46.7)

0.034

Typical

194 (77.9)

63 (78.8)

131 (77.5)

0.17

Atypical

27 (10.8)

4 (5.0)

23 (13.6)

0.08

Indeterminate appearance

5 (2.0)

1 (1.3)

4 (2.4)

1.00

Negative

4 (1.6)

2 (2.5)

2 (1.2)

0.59

No CT scan

19 (7.6)

10 (12.5)

9 (5.3)

0.71

Chest CT Compatibility

All values are expressed as numbers (percentages) or median (interquartile range).
Abbreviations: CT, computed tomography; WBC, white blood cell; BUN, blood urea nitrogen; CRP, C-reactive protein;
AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; HS Troponin I, high-sensitive
troponin I; BNP, brain natriuretic peptide; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of
arterial oxygen; SO2, arterial oxygen saturation; FiO2, fraction of Inspired oxygen.
a
Tested on the day of ICU admission.
b
Collected percutaneously or via a central vein.
c
Performed on the day of hospital admission.

39% [16]. This wide variability may be in consequence
of various factors such as patient characteristics, disease
severity in different populations, the spreading rate of the
disease, the stress on healthcare systems, ICU admission
practices and follow-up time in the studies.
In literature, there is limited data for the relationship
between involvement in lungs and mortality in COVID-19.
In this study, the higher points of the chest CT score were
associated with poor prognosis. We have found that a
chest CT score > 15 on hospital admission independently
increases the risk of death. Likewise, a recent study
revealed that a CT score ≥ 18 is highly predictive of
short-term mortality in patients with COVID-19 [19].
Additionally, the chest CT score correlates with age,
oxygen requirement, and disease progression [19–21].
As a result, we suggest that the chest CT score calculated
on the day of hospital admission has a remarkable value
owing to present a prediction for the disease progression
and 28-day mortality.
Organ impairments such as cardiac or renal injury,
and coinfections causing sepsis/septic shock were found
as another independent risk factors for 28-day mortality

in this study. The relationship between organ failure
and increased mortality is usual in ICU. However, acute
kidney injury, cardiac injury, and secondary infections
are the conditions that should be prevented or needed
close monitoring in critically ill patients with COVID-19.
In the laboratory data, findings indicating infection,
inflammation, myocardial injury, or abnormal cardiac
function, as well as abnormal renal function and fluid
overload were significantly high in the deceased group as
in previous studies [3–8,19,20].
In the univariate analysis, symptoms, expectoration,
and anorexia; and comorbidities, cerebrovascular disease,
dementia, chronic kidney disease, and malignancy were
associated with mortality. Additionally, high values of
APACHE II and SOFA scores, and CCI were related to
28-day mortality. In a previous study, dyspnea was defined
as a risk factor for mortality [3], but, in this study, it did
not differ between groups. A study from Wuhan revealed
that anorexia is more frequent in nonsurvivor patients
[22]. In previous studies, hypertension [7,8,22], diabetes
mellitus [7], chronic heart disease [5,7], chronic lung
disease [22], cerebrovascular disease [3,7], chronic kidney
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Table 3. Treatments and Complications of the patients.
28-day status
All cases
(n=249)

Recovered group
(n=80)

Deceased group
(n=169)

P Value

Favipiravir

239 (96.0)

80 (100.0)

159 (94.1)

0.033

Hydroxychloroquine

54 (21.7)

16 (20.0)

38 (22.5)

0.74

LMWH

237 (95.2)

77 (96.3)

160 (94.7)

0.76

ASA

193 (77.5)

60 (75.0)

133 (78.7)

0.52

Dipyridamole

152 (61.0)

42 (52.5)

110 (65.1)

0.07

Corticosteroids

195 (78.3)

61 (76.3)

134 (79.3)

0.62

Pulse corticosteroidb

101 (40.6)

29 (36.3)

72 (42.6)

0.41

Tocilizumab

25 (10.0)

10 (12.5)

15 (8.9)

0.38

Convalescent plasma

70 (28.1)

28 (35.0)

42 (24.9)

1.00

Use of vasopressorc

165 (66.3)

22 (27.5)

143 (84.6)

< 0.001

RRT

65 (26.1)

7 (8.8)

58 (34.3)

< 0.001

COT

20 (8.0)

18 (22.5)

2 (1.2)

< 0.001

HFNC

90 (36.1)

42 (52.5)

48 (28.4)

< 0.001

NIMV

43 (17.3)

12 (15.0)

31 (18.3)

0.52

IMV

192 (77.1)

27 (33.8)

165 (97.6)

< 0.001

ECMO

3 (1.2)

0 (0.0)

3 (1.8)

0.23

Sepsis/septic shock

166 (66.7)

18 (22.5)

148 (87.6)

< 0.001

AKI

139 (55.8)

14 (17.5)

125 (74.0)

< 0.001

VAP

118 (47.4)

16 (20.0)

102 (60.4)

< 0.001

Acute cardiac injury

60 (24.1)

6 (7.5)

54 (32.0)

< 0.001

New-onset arrhythmia

50 (20.1)

10 (12.5)

40 (23.7)

0.043

CPR

9 (3.6)

2 (2.5)

7 (4.1)

0.72

PTE

5 (2.0)

3 (3.8)

2 (1.2)

0.33

Treatment

a

Respiratory Support

Complications

All values are expressed as numbers (percentages) or median (interquartile range).
Abbreviations: LMWH, low molecular weight heparin; ASA, acetylsalicylic acid; RRT, renal replacement therapy;
COT, conventional oxygen therapy; HFNC, high flow nasal cannula; NIMV, noninvasive mechanical ventilation;
IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation; AKI, acute kidney injury; VAP,
ventilator-associated pneumonia; CPR, cardiopulmonary resuscitation; PTE, pulmonary thromboembolism.
a
Intravenous methylprednisolone 0.5–1 mg/kg/day.
b
Intravenous methylprednisolone > 250 mg/day.
c
Norepinephrine > 0.15 µg/kg/min.

disease, and chronic liver disease [3], malignancy [5],
and immunosuppression [7] were defined as risk factors
for mortality. Although dementia and malignancy were
significantly high in the deceased group, both comorbidities
were not considered risk factors for 28-day survival in
the multivariate analysis. There is still wide variability in
the definition of comorbidities, symptoms, and signs as
mortality risk factors in patients with COVID-19.
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The data of the microbiological cultures showed that
one or more positive blood or respiratory sample culture
had a crucial impact on survival. Especially, a positive
Acinetobacter spp. or Klebsiella spp. in tracheal aspirate
sample culture was related to 28-day mortality. Lansbury et
al. [23] evaluated 3834 COVID-19 pneumonia and showed
Acinetobacter baumannii and Klebsiella pneumoniae in
two and four patients, respectively. Compared with the
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Table 4. Logistic regression analysis for independent risk factors
of 28-day mortality in critically ill patients with COVID-19.
OR (95% CI)

P Value

Sepsis/Septic Shock

15.16 (3.96–58.11)

< 0.001

AKI

4.73 (1.55–14.46)

0.006

Acute cardiac injury

9.76 (1.84–51.83)

0.007

VAP

2.23 (0.66–7.61)

0.20

CT Score > 15

4.49 (1.51–13.38)

0.007

APACHE II score

1.02 (0.95–1.10)

0.53

Dementia

3.94 (0.35–40.28)

0.26

Malignancy

1.20 (0.18–8.05)

0.85

Sex

1.45 (0.49–4.33)

0.51

Abbreviations: OR, odds ratio; AKI, acute kidney injury;
VAP, ventilator-associated pneumonia; CT score, computed
tomography score; APACHE II, Acute Physiology and Chronic
Health Evaluation II.

low incidence of the prior data, a high incidence of these
pathogens was notable in this study. Additionally, VAP
was a major causative problem for death, but it was not an
independent risk factor mortality in multivariate analysis.
According to the time of admission and
recommendations in the national guideline, most
patients received different antiviral agents. In univariate
analysis, only favipiravir was used more commonly in
the survivors in our cohort. There is still no evidence
whether an antiviral agent has a beneficial effect on the
recovery of COVID-19 [24]. The RECOVERY trial [25]
revealed that dexamethasone and tocilizumab reduce
mortality and the need for MV, but, in patients who receive
corticosteroids, secondary infections may increase with
delayed viral clearance [26–28]. Additionally, tocilizumab
was considered shortening the discharge time [25]. In
contrast, the use of both tocilizumab, and pulse/usual dose
of corticosteroids did not reduce the risk of mortality in
our study. This issue may be related to the retrospective
design and small sample size. Also, we did not evaluate
the discharge time and need for MV in patients receiving
tocilizumab. Simonovich et al [29] showed that the use
of convalescent plasma therapy in addition to standard
of care did not reduce 30-day mortality in patients with
severe pneumonia. In this study, the use of convalescent
plasma therapy did not significantly differ between the
groups.
Many kinds of respiratory support modalities revealed
a significant effect on mortality. The need for NIV or IMV
on hospital or ICU admission is associated with mortality
compared with the COT or HFNC [8]. A study showed
that survival was higher in patients who received COT,

HFNC, or NIV compared with patients needed for IMV
in the first 24 h [6]. Our data revealed that COT and
HFNC were significantly high in the recovered patients,
and patients who needed IMV had a high 28-day mortality
rate. Additionally, in the laboratory data, the parameters
related to severe respiratory failure including low oxygen
saturation on ICU admission, hypoxemia, decreased
global oxygen delivery, increased anaerobic metabolism,
and acidosis were strongly associated with mortality.
Likewise, a low PaO2 / FiO2 ratio on ICU admission was
independently associated with mortality in a previous
study [6]. Rapid progression of the disease, need for more
advanced respiratory support may cause high mortality in
patients with severe disease. However, delayed admission
to ICU may be another reason for mortality, but, in this
cohort, the duration from the first symptom to hospital or
ICU admission did not differ between groups.
5. Limitations and strengths
This study has several limitations. First, the results
are from a single center and should be supported by
further studies. Second, acquired data was based on the
retrospective evaluation of the records. We did not achieve
some patients’ previous chest CT scans due to transfer
from another center. Third, we could not analyze the longterm survival of the patients. However, the study has some
strengths. We think that momentary data in ICUs for the
conditions related to mortality provides a valuable data
set. Second, reevaluation of the chest CT scans with a high
interrater agreement, made this parameter more reliable.
6. Conclusion
In the present study, we revealed that sepsis/septic shock,
AKI, acute cardiac injury, a CT score > 15 were the
independent risk factors related to mortality in critically
ill patients with COVID-19. Risk stratification in these
patients, especially in the peak periods of the outbreak,
is essential to the appropriate use of limited healthcare
sources. Early prediction of the disease progression may
contribute to this principle. It is also vital for patients who
have a high risk of death. The results of the present study
may improve the outcomes of the patients with COVID-19.
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